Clinical Trial Update: Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating orelabrutinib combined with zebetuzumab and lenalidomide for newly diagnosed marginal zone lymphoma is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Orelabrutinib (orelabrutinib)
• Zebetuzumab (zebetuzumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Marginal Zone Lymphoma(MZL) | Phase 2 | Status: RECRUITING